Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration

Rispah T. Sawe, Maggie Kerper, Sunil Badve, Jun Li, Mayra Sandoval-Cooper, Jingmeng Xie, Zonggao Shi, Kirtika Patel, David Chumba, Ayub Ofulla, Jenifer Prosperi, Katherine Taylor, M. Sharon Stack, Simeon Mining, Laurie E. Littlepage

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Breast cancer incidence and mortality vary significantly among different nations and racial groups. African nations have the highest breast cancer mortality rates in the world, even though the incidence rates are below those of many nations. Differences in disease progression suggest that aggressive breast tumors may harbor a unique molecular signature to promote disease progression. However, few studies have investigated the pathology and clinical markers expressed in breast tissue from regional African patient populations. Methods: We collected 68 malignant and 89 non-cancerous samples from Kenyan breast tissue. To characterize the tumors from these patients, we constructed tissue microarrays (TMAs) from these tissues. Sections from these TMAs were stained and analyzed using immunohistochemistry to detect clinical breast cancer markers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 receptor (HER2) status, Ki67, and immune cell markers. Results: Thirty-three percent of the tumors were triple negative (ER-, PR-, HER2-), 59 % were ER+, and almost all tumors analyzed were HER2-. Seven percent of the breast cancer patients were male, and 30 % were

Original languageEnglish (US)
Article number204
JournalBMC Cancer
Volume16
Issue number1
DOIs
StatePublished - Mar 10 2016

Fingerprint

Kenya
Cell Proliferation
Breast Neoplasms
Estrogen Receptors
Progesterone Receptors
Disease Progression
Breast
Biomarkers
Neoplasms
Mortality
Incidence
Immunohistochemistry
Pathology
Population

Keywords

  • Breast cancer
  • CD163
  • CD25
  • Estrogen receptor
  • Kenya

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration. / Sawe, Rispah T.; Kerper, Maggie; Badve, Sunil; Li, Jun; Sandoval-Cooper, Mayra; Xie, Jingmeng; Shi, Zonggao; Patel, Kirtika; Chumba, David; Ofulla, Ayub; Prosperi, Jenifer; Taylor, Katherine; Stack, M. Sharon; Mining, Simeon; Littlepage, Laurie E.

In: BMC Cancer, Vol. 16, No. 1, 204, 10.03.2016.

Research output: Contribution to journalArticle

Sawe, RT, Kerper, M, Badve, S, Li, J, Sandoval-Cooper, M, Xie, J, Shi, Z, Patel, K, Chumba, D, Ofulla, A, Prosperi, J, Taylor, K, Stack, MS, Mining, S & Littlepage, LE 2016, 'Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration', BMC Cancer, vol. 16, no. 1, 204. https://doi.org/10.1186/s12885-016-2204-6
Sawe, Rispah T. ; Kerper, Maggie ; Badve, Sunil ; Li, Jun ; Sandoval-Cooper, Mayra ; Xie, Jingmeng ; Shi, Zonggao ; Patel, Kirtika ; Chumba, David ; Ofulla, Ayub ; Prosperi, Jenifer ; Taylor, Katherine ; Stack, M. Sharon ; Mining, Simeon ; Littlepage, Laurie E. / Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration. In: BMC Cancer. 2016 ; Vol. 16, No. 1.
@article{9a238b7e806f4b528938e6db7e92a646,
title = "Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration",
abstract = "Background: Breast cancer incidence and mortality vary significantly among different nations and racial groups. African nations have the highest breast cancer mortality rates in the world, even though the incidence rates are below those of many nations. Differences in disease progression suggest that aggressive breast tumors may harbor a unique molecular signature to promote disease progression. However, few studies have investigated the pathology and clinical markers expressed in breast tissue from regional African patient populations. Methods: We collected 68 malignant and 89 non-cancerous samples from Kenyan breast tissue. To characterize the tumors from these patients, we constructed tissue microarrays (TMAs) from these tissues. Sections from these TMAs were stained and analyzed using immunohistochemistry to detect clinical breast cancer markers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 receptor (HER2) status, Ki67, and immune cell markers. Results: Thirty-three percent of the tumors were triple negative (ER-, PR-, HER2-), 59 {\%} were ER+, and almost all tumors analyzed were HER2-. Seven percent of the breast cancer patients were male, and 30 {\%} were",
keywords = "Breast cancer, CD163, CD25, Estrogen receptor, Kenya",
author = "Sawe, {Rispah T.} and Maggie Kerper and Sunil Badve and Jun Li and Mayra Sandoval-Cooper and Jingmeng Xie and Zonggao Shi and Kirtika Patel and David Chumba and Ayub Ofulla and Jenifer Prosperi and Katherine Taylor and Stack, {M. Sharon} and Simeon Mining and Littlepage, {Laurie E.}",
year = "2016",
month = "3",
day = "10",
doi = "10.1186/s12885-016-2204-6",
language = "English (US)",
volume = "16",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration

AU - Sawe, Rispah T.

AU - Kerper, Maggie

AU - Badve, Sunil

AU - Li, Jun

AU - Sandoval-Cooper, Mayra

AU - Xie, Jingmeng

AU - Shi, Zonggao

AU - Patel, Kirtika

AU - Chumba, David

AU - Ofulla, Ayub

AU - Prosperi, Jenifer

AU - Taylor, Katherine

AU - Stack, M. Sharon

AU - Mining, Simeon

AU - Littlepage, Laurie E.

PY - 2016/3/10

Y1 - 2016/3/10

N2 - Background: Breast cancer incidence and mortality vary significantly among different nations and racial groups. African nations have the highest breast cancer mortality rates in the world, even though the incidence rates are below those of many nations. Differences in disease progression suggest that aggressive breast tumors may harbor a unique molecular signature to promote disease progression. However, few studies have investigated the pathology and clinical markers expressed in breast tissue from regional African patient populations. Methods: We collected 68 malignant and 89 non-cancerous samples from Kenyan breast tissue. To characterize the tumors from these patients, we constructed tissue microarrays (TMAs) from these tissues. Sections from these TMAs were stained and analyzed using immunohistochemistry to detect clinical breast cancer markers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 receptor (HER2) status, Ki67, and immune cell markers. Results: Thirty-three percent of the tumors were triple negative (ER-, PR-, HER2-), 59 % were ER+, and almost all tumors analyzed were HER2-. Seven percent of the breast cancer patients were male, and 30 % were

AB - Background: Breast cancer incidence and mortality vary significantly among different nations and racial groups. African nations have the highest breast cancer mortality rates in the world, even though the incidence rates are below those of many nations. Differences in disease progression suggest that aggressive breast tumors may harbor a unique molecular signature to promote disease progression. However, few studies have investigated the pathology and clinical markers expressed in breast tissue from regional African patient populations. Methods: We collected 68 malignant and 89 non-cancerous samples from Kenyan breast tissue. To characterize the tumors from these patients, we constructed tissue microarrays (TMAs) from these tissues. Sections from these TMAs were stained and analyzed using immunohistochemistry to detect clinical breast cancer markers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 receptor (HER2) status, Ki67, and immune cell markers. Results: Thirty-three percent of the tumors were triple negative (ER-, PR-, HER2-), 59 % were ER+, and almost all tumors analyzed were HER2-. Seven percent of the breast cancer patients were male, and 30 % were

KW - Breast cancer

KW - CD163

KW - CD25

KW - Estrogen receptor

KW - Kenya

UR - http://www.scopus.com/inward/record.url?scp=84960331919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960331919&partnerID=8YFLogxK

U2 - 10.1186/s12885-016-2204-6

DO - 10.1186/s12885-016-2204-6

M3 - Article

C2 - 26964534

AN - SCOPUS:84960331919

VL - 16

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 204

ER -